Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells.
Dendritic cells (DCs) are professional antigen-presenting cells (APCs) that can be used for vaccination purposes, to induce a specific T-cell response in vivo against melanoma-associated antigens. We have shown that the sequential use of early-acting hematopoietic growth factors, stem cell factor, I...
Auteurs principaux: | Mackensen, A, Herbst, B, Chen, J, Köhler, G, Noppen, C, Herr, W, Spagnoli, G, Cerundolo, V, Lindemann, A |
---|---|
Format: | Journal article |
Langue: | English |
Publié: |
2000
|
Documents similaires
-
Induction of antigen-specific immune responses in melanoma patients after vaccination with peptide-pulsed dendritic cells.
par: Mackensen, A, et autres
Publié: (1999) -
Dendritic Cell Lineage Potential in Human Early Hematopoietic Progenitors
par: Julie Helft, et autres
Publié: (2017-07-01) -
Clinical response in Japanese metastatic melanoma patients treated with peptide cocktail-pulsed dendritic cells
par: Takesako Kazutoh, et autres
Publié: (2005-01-01) -
Transient loading of CD34+ hematopoietic progenitor cells with polystyrene nanoparticles
par: Deville S, et autres
Publié: (2017-01-01) -
Generation and function of progenitor T cells from StemRegenin-1–expanded CD34+ human hematopoietic progenitor cells
par: Jastaranpreet Singh, et autres
Publié: (2019-10-01)